Now I have all the information I need. Let me write the consolidated review.

## Summary
This paper introduces Constrained Mass Transport (CMT), a variational framework that constructs annealing paths for sampling from unnormalized Boltzmann distributions. CMT imposes joint constraints on both KL divergence (trust-region) and entropy decay between successive intermediate distributions, yielding a geometric-tempered annealing path with closed-form analytical solutions (Propositions 2.1–2.3, Theorem 2.4). The method is instantiated with normalizing flows and evaluated on four molecular systems (up to d=219), including the new ELIL tetrapeptide benchmark. CMT consistently achieves the best or near-best EUBO and ESS across all systems while using the same or fewer target evaluations than strong baselines (FAB, TA-BG).

## Strengths
- **Theoretically grounded dual-constraint framework**: Propositions 2.1–2.3 derive closed-form intermediate densities for trust-region, entropy, and combined constraints. Theorem 2.4 proves that the combined constraints produce a geometric-tempered annealing path with monotonic β schedule. This goes beyond prior work (Blessing et al., 2025) by adding the entropy constraint and characterizing its effect on the path.
- **Consistent and substantial empirical improvements**: On the two largest systems (alanine hexapeptide d=180, ELIL tetrapeptide d=219), CMT achieves 29.63% ESS vs. 18.22% (TA-BG) and 26.06% vs. 13.75% (TA-BG) respectively — roughly 1.6–1.9× improvement over the strongest baseline. CMT also achieves the best (lowest) EUBO on all four systems, demonstrating reliable mode coverage (Table 1).
- **Introduction of a challenging new benchmark**: The ELIL tetrapeptide (d=219, 4 residues with complex side-chain interactions) is the largest molecular system studied to date under the purely energy-based variational sampling setting, providing a more demanding test for future methods.
- **Ablation study validates both constraints**: Figures 2–3 systematically compare no-constraint, trust-region only, entropy-only, and combined variants on alanine hexapeptide. The combined variant avoids the mode collapse visible in single-constraint variants while maintaining high ESS, confirming the necessity of both constraints.
- **Negligible computational overhead**: The Lagrangian dual optimization accounts for only ~0.01% of total training time (alanine dipeptide), demonstrating practical efficiency.

## Weaknesses

### Fatal
None.

### Major
- **Overclaimed "2.5× higher ESS" in abstract and conclusion**: The paper states "achieving more than 2.5× higher effective sample size" (lines 17, 272). The maximum improvement over the *strongest baseline* (TA-BG) is ≈1.90× on ELIL tetrapeptide (26.06%/13.75%) and ≈1.63× on alanine hexapeptide (29.63%/18.22%). Even against the weaker FAB baseline the ratio is ≈2.04×. The 2.5× figure does not appear in the data. This is a clear overstatement that should be corrected to reflect the actual range of relative improvements (1.6–1.9× over TA-BG; up to ~2× over FAB). The same issue applies to line 246's "approximately twice the ESS" which is reasonable for FAB but exaggerated against the stronger TA-BG baseline.

- **Overclaimed "consistently surpasses" language**: The abstract and conclusion claim CMT "consistently surpasses state-of-the-art approaches" (lines 17, 272). But Table 1 shows that on ELIL tetrapeptide, CMT achieves *worse* Ram TV (3.13×10⁻²) than TA-BG (2.54×10⁻²). The paper reports this number but does not discuss or explain the discrepancy. "Consistently" is too strong — the paper should qualify this (e.g., "on most metrics across all systems") or discuss the trade-off explicitly.

### Minor
- **Missing quantitative Ram TV for ablation study**: The ablation study (Figures 2–3) uses visual inspection of Ramachandran plots to argue that single-constraint variants suffer mode collapse. Quantitative Ram TV values for each constraint variant (no constraint, geometric only, tempered only, geometric-tempered) would make the argument more rigorous and replace qualitative judgment with measurable evidence.
- **No discussion of the ELIL Ram TV gap**: CMT is slightly worse than TA-BG on Ram TV for ELIL (3.13×10⁻² vs. 2.54×10⁻²). The paper does not offer any explanation. A brief comment on whether this reflects a genuine trade-off (e.g., the tempered path better captures certain modes in larger systems) would improve transparency.
- **Statistical significance not discussed for small gaps**: On alanine tetrapeptide, CMT's ESS (68.60%) is only 2.8 percentage points above TA-BG (65.81%). The paper reports standard errors but does not comment on whether this difference is practically or statistically meaningful.

### Trivial
- The notation in Proposition 2.3 equation (10) has an extra `(x)` in the integrand (`...\tilde{p}(x)^{\frac{1}{1+\lambda+\eta}} (x) dx`) — likely a LaTeX formatting artifact.

## Nice-to-Haves
- A summary table showing the relative ESS improvement of CMT over each baseline per system would help the reader quickly gauge results without computing ratios manually.
- A brief discussion of how the computational overhead of dual optimization scales with system dimensionality beyond the alanine dipeptide 0.01% figure would be informative.

## Removed Points
These points from the inputs were removed or demoted with justification:

- **"Largest system to date claim unverifiable"** (Harsh Critic): The paper uses the qualifier "to the best of our knowledge" (line 45). This is appropriately cautious and standard for such claims. No evidence contradicts it. → REMOVED.
- **"Trust-region constraint controlling variance independent of dimension — unverifiable without appendix"** (Harsh Critic): The paper references Appendix C.3 for the proof. Per instructions, missing appendix content should not be penalized. The claim itself may be bold but cannot be assessed as false without the appendix. → REMOVED.
- **"Missing related works"**: Per instructions, I cannot verify claims about missing related works without external sources. → REMOVED.
- **Strength Finder #1's claim that the 2.5× figure is supported by data**: This is factually incorrect — 26.06%/13.75% = 1.90×, not 2.5×. The strength (CMT achieves substantially higher ESS) is real but the specific 2.5× claim is not supported. → WEAKENED in the strength statement above.
- **Formatting/typo nitpicks**: Per instructions, parser artifacts and typos should not be flagged. → REMOVED.
- **"Largest system to date claim should include comparison table"** (Harsh Critic): Nice-to-have but not a weakness of the paper's core contribution. → DEMOTED to Nice-to-Haves.

## Novel Insights
None beyond the paper's own contributions.

## Suggestions
1. Correct the "2.5× higher ESS" claim in the abstract and conclusion to reflect the actual range (1.6–1.9× over TA-BG; up to ~2.0× over FAB).
2. Replace "consistently surpasses" with more precise language acknowledging the Ram TV exception on ELIL tetrapeptide, or add a sentence discussing the trade-off.
3. Report quantitative Ram TV values for each constraint variant in the ablation study to replace qualitative visual assessment.

## Score and Decision

**Calibration anchors:**

| Anchor | Score | Comparison |
|--------|-------|-----------|
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/pRCOZllZdT.md` | 7.00 (Accept) | BoPITO: tested on alanine dipeptide only (2 systems). CMT tests on 4 systems up to d=219, with more baselines. CMT is empirically stronger. |
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/TUvg5uwdeG.md` | 6.40 (Accept) | Neural Sampling: experiments limited to 2D/8D. CMT demonstrates real molecular benchmarks up to d=219. Much stronger empirical validation. |
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/ybWOYIuFl6.md` | 6.00 (Reject) | BNEM: tested only on toy systems (2D GMM, 4-particle DW). CMT is substantially more thorough. |
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/D2EdWRWEQo.md` | 5.50 (Reject) | FreeFlow: limited benchmarks, missing comparisons. CMT has proper baselines and more systems. |
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/kKXIYUi8ff.md` | 3.00 (Reject) | DynamicsDiffusion: poor presentation, limited novelty. CMT is far stronger. |
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/H380m98pLE.md` | 2.50 (Reject) | Unrelated topic (constrained GP regression). Low-quality submission. |
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/NSVtmmzeRB.md` | 8.00 (Accept) | GeoBFN: SOTA molecular generation. Different subproblem (generating conformers from data vs sampling from energy). Not directly comparable. |
| `/home/wg25r/split_review/datasets/deepreview_13k_calibration/FBkpCyujtS.md` | 8.50 (Accept) | Unrelated topic (LLM text generation via min-p sampling). Not comparable. |

Relative to the most relevant anchors (BoPITO 7.0, Neural Sampling 6.4, BNEM 6.0), CMT is clearly stronger empirically — testing on larger and more systems with proper baselines. Its theoretical contribution (joint trust-region+entropy constraints with closed-form solutions) is novel and well-supported. The main weaknesses are presentation overclaims (2.5× ESS, "consistently surpasses") which are correctable, not structural flaws. This places CMT above the ∼6.5 range of the BNEM/Neural Sampling papers and comparable to or slightly above the 7.0 BoPITO paper.

MY FINAL SCORE: <score>7.0</score>
MY FINAL DECISION: <decision>Accept</decision>